PQQ and mitochondrial energy: a great mechanism in search of human proof

Why PQQ became the “new mitochondria” supplement

Most energy supplements promise to feed your existing mitochondria. PQQ promises something bolder: to build you new ones. That is the entire reason pyrroloquinoline quinone — a small, redox-active compound found in trace amounts in foods like fermented soy, kiwi, and green peppers — commands a premium and gets stacked into nearly every “cellular energy” formula on the shelf. The pitch is irresistible: more mitochondria, more ATP, more energy, sharper brain, slower aging.

And unlike a lot of supplement marketing, the first link in that chain has serious laboratory support. PQQ really does activate the cellular program that creates new mitochondria. That single fact is what separates PQQ from pure snake oil and lands it in the genuinely-interesting pile. The problem is everything that's supposed to follow from it. A mechanism that fires beautifully in a petri dish does not automatically translate into a person feeling more energetic — and with PQQ, the gap between the dish and the human is exactly where the story gets thin.

So this is a hype-check, run fairly. The mechanism deserves respect. The consumer promise deserves scrutiny. Let's hold both at once — the line this publication exists to hold. For the wider category, see our Energy & Performance hub.

The mechanism: how PQQ pulls the biogenesis signal

Here the technical vocabulary earns its place, so the jargon is allowed. Mitochondria don't just divide on their own — their production is governed by a master regulator called PGC-1α (peroxisome proliferator-activated receptor-gamma coactivator-1-alpha), the cellular conductor that orchestrates mitochondrial biogenesis. When PGC-1α is switched on, it recruits downstream factors (NRF-1, NRF-2, and Tfam) that ramp up the building of new mitochondria. The signal it pulls is, in effect, “build more power plants.”

The landmark mechanistic study, published in 2010, showed that PQQ pulls exactly this lever. In mouse liver cells, PQQ stimulated phosphorylation of CREB (cAMP response element-binding protein), which in turn activated the PGC-1α promoter and raised PGC-1α expression — followed by measurable increases in mitochondrial DNA content, cellular respiration, and the markers of new mitochondria. Crucially, when the researchers silenced either CREB or PGC-1α, PQQ's effect vanished, confirming the pathway is genuinely doing the work¹. Later work added a second route, implicating the SIRT1/PGC-1α axis — the same longevity-linked signaling that fasting and exercise recruit².

PQQ also behaves as an unusually durable redox cofactor — it can cycle through thousands of oxidation-reduction reactions without breaking down, which underpins its antioxidant reputation. But the headline mechanism is the biogenesis one, and it is the cleanest part of the entire PQQ story. The honest caveat sits one level down: nearly all of this was established in cultured cells and rodents. A mechanism being well-mapped is not the same as a mechanism mattering in a living human at a supplement dose — which is precisely why this claim grades Emerging, not Strong.

PQQ clearly knows how to tell a cell to build mitochondria. Whether that message changes how a person feels is the question the human trials still haven't answered.

What the human trials actually show

Move from the dish to the human and the literature shrinks fast. The PQQ human evidence base is not a wall of large randomized trials — it is a short shelf of small ones, several of them open-label, several funded by manufacturers, and most running for weeks rather than months. That doesn't make them worthless. It makes them hypothesis-generating. Here is the honest map of what exists.

Two patterns jump out. First, the human work is consistently small — sample sizes in the teens to low forties, durations measured in weeks. Second, the studies most favorable to the consumer pitch tend to be the ones run or funded by PQQ manufacturers (the foundational fatigue and cognition trials trace back to Mitsubishi Gas Chemical, which commercializes a branded PQQ). None of that invalidates the signals. It does mean they need independent, larger replication before anyone calls them proven.

Fatigue and sleep: a real but fragile signal

The most-cited human result is also one of the shakiest by design. In a 2012 study, 17 adults took 20 mg of PQQ daily for eight weeks, and by the end reported significant improvements across mood measures — vigor, fatigue, tension, depression, confusion — alongside better scores for sleep onset, maintenance, and waking refreshment³. Read at face value, that's an encouraging result on exactly the outcomes people buy PQQ for.

Read critically, the caveats are heavy. It was open-label — no placebo group, so everyone knew they were taking the active compound, and self-reported fatigue and sleep are precisely the kind of soft endpoints that move on expectation alone. The sample was tiny. And it was conducted by a PQQ manufacturer. A short, unblinded, manufacturer-run study showing better questionnaire scores is a reason to run a real placebo-controlled trial, not a reason to declare the question answered. A single open-label study on soft, expectation-sensitive endpoints is the textbook definition of weak evidence — which is why this one grades Weak, not Emerging. The signal is worth tracking; it is nowhere near established.

Adjacent to fatigue sits inflammation. A small crossover study in 10 people found that short-term PQQ lowered circulating C-reactive protein and IL-6 — markers of systemic inflammation — and shifted some urinary metabolites tied to mitochondrial metabolism⁵. It's a mechanistically tidy finding that fits the biogenesis story, but with ten subjects over 76 hours, it's a clue, not a conclusion.

Cognition and brain energy

The brain burns a disproportionate share of the body's energy, so a biogenesis story naturally extends to cognition — and a couple of small trials have chased it. A 2016 randomized, placebo-controlled study of 41 adults using a branded PQQ reported gains on some cognitive subscales over 12 weeks, particularly in measures tied to attention and working memory⁶. It's a properly blinded design, which is a step up from the fatigue work — but it's still small, industry-funded, and selective in which endpoints moved.

The most recent entry is more interesting. A 2024 randomized controlled trial gave a dihydrogen-PQQ formulation to 34 older adults with mild cognitive impairment for six weeks and measured brain physiology directly: cerebral oxygenation saturation rose meaningfully from baseline, alongside changes in mitochondrial biomarkers and some cognitive measures⁷. Measuring an objective physiological endpoint — brain oxygen use — rather than just questionnaire scores is exactly the kind of rigor the field needs more of. But it's still 34 people over six weeks, in a specific clinical population, and it needs replication at scale before it says anything about a healthy person hoping for sharper focus. Promising, genuinely — settled, no.

Energy in healthy people: where the headline breaks

This is the claim that sells the bottles, and it's the one the cleanest human study quietly undercuts. In a 2020 randomized controlled trial, 23 untrained men took either 20 mg of PQQ daily or placebo while completing six weeks of supervised endurance training. The training worked — both groups improved their peak oxygen consumption and exercise duration. But here's the tell: there was no significant difference between the PQQ and placebo groups in any aerobic-performance or body-composition outcome. PQQ added nothing the training didn't already deliver⁴.

What makes this study so useful is what it measured alongside performance. The PQQ group did show a significant rise in PGC-1α protein — the very biogenesis signal the marketing leans on — relative to placebo. So the mechanism fired exactly as advertised. And the felt, measurable outcome didn't budge. That is the entire PQQ tension captured in one trial: the supplement pulled the biogenesis lever, and it changed nothing the person could feel or perform. Building the machinery is not the same as producing more usable energy.

Read precisely, then, “PQQ is a proven energy booster” is not supported. The honest position is that PQQ may modestly shift biological markers in healthy people while leaving the thing they actually want — more energy, better performance — untouched in the trials done so far. For a healthy adult chasing a lift, that earns a Weak grade. The fix for ordinary fatigue is far more likely to be sleep, training, iron and thyroid status, and the basics — the same conclusion we reached for its shelf-mate in our CoQ10 and ubiquinol evidence review.

The CoQ10 stack and how to read a PQQ label

PQQ is most often sold beside CoQ10, and the pairing has a clean logic: CoQ10 helps your existing mitochondria run the electron transport chain, while PQQ is pitched as building more of them. Two complementary jobs, one capsule. The theory is reasonable. The evidence that the combination beats either ingredient alone, for energy in healthy people, essentially doesn't exist — the few combo studies are small and don't isolate what PQQ adds on top of CoQ10⁶. So the stack is a sensible hypothesis being marketed as an established synergy. That gap is why it grades Weak.

This framework is not a prescription — it's a way to read what the trials actually used, so you can interpret a label honestly rather than be sold by it. We don't tell anyone to take PQQ.

• Foundational (what most trials used): 20 mg/day of PQQ is the dose behind the fatigue, cognition, and exercise studies. If a product is dramatically over- or under-dosing that, it's drifting away from the (already thin) evidence.
• Research-curious (the CoQ10 context): the trials that paired PQQ with CoQ10 don't prove synergy, so treat a combo product as buying two separate supplements — judge each on its own data, and remember CoQ10's strongest evidence is in heart failure, not energy.
• Experimental (everything past that): mega-doses, proprietary blends, and “mitochondrial stacks” that pile PQQ with a dozen other compounds sit entirely outside the trial evidence. There's no human data telling you what those combinations do.

The grey areas

A few honest uncertainties sit underneath the grades. The trials are small, short, and often conflicted. The most consumer-friendly results come from manufacturer-run studies on a few dozen people over a few weeks — the exact conditions under which positive findings should be treated as preliminary. Dose and form are unsettled: most studies cluster around 20 mg/day, but newer formulations like dihydro-PQQ may behave differently, and there's no consensus on an optimal dose for any outcome. And the deepest grey area is conceptual: biogenesis is not the same as felt energy. The Hwang trial⁴ is the clearest reminder — PGC-1α can rise while performance stays flat. A supplement can move a biomarker and still do nothing you'd notice. PQQ has a real safety record at these doses, but a clean safety profile is not the same as a proven benefit.

What we still don't know

Three honest gaps. First, there is no large, independent, placebo-controlled trial of PQQ for energy or fatigue in healthy adults — the existing fatigue evidence is open-label and manufacturer-run³, and the cleanest performance trial found no benefit over placebo⁴; settling the headline claim would take exactly the study nobody has run yet. Second, the cognition signal needs replication outside small, often-funded samples — the 2024 brain-oxygenation result is intriguing⁷, but it lives in 34 older adults with mild impairment, not the healthy users the marketing targets. Third, the leap from mechanism to outcome remains unproven in humans — PQQ clearly pulls the PGC-1α signal¹, yet whether that reliably produces anything a person experiences is the question the whole field is still missing the data to answer. None of that makes PQQ a scam. It makes it a fascinating mechanism with a consumer promise that has run well ahead of its evidence — sold as proven, graded as emerging.